Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06139328
Registration number
NCT06139328
Ethics application status
Date submitted
7/11/2023
Date registered
18/11/2023
Date last updated
8/07/2025
Titles & IDs
Public title
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
Query!
Scientific title
Randomised Study for Double-blind, Placebo-controlled Evaluation of a Single Intravenous Infusion of BI 765845 and Partially-blinded Evaluation of a Single Bolus Administration of BI 765845 on Top of Standard of Care in Patients With Acute Myocardial Infarction
Query!
Secondary ID [1]
0
0
U1111-1291-6320
Query!
Secondary ID [2]
0
0
1478-0002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IRI-EXPLORE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Myocardial Infarction
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BI 765845
Treatment: Drugs - Placebo matching BI 765845
Experimental: BI 765845 very low dose group, administration type 1 -
Experimental: BI 765845 low dose group, administration type 1 -
Experimental: BI 765845 medium dose group, administration type 1 -
Experimental: BI 765845 high dose group, administration type 1 -
Placebo comparator: Placebo group -
Experimental: BI 765845 low dose group, administration type 2 -
Experimental: BI 765845 high dose group, administration type 2 -
Treatment: Drugs: BI 765845
BI 765845
Treatment: Drugs: Placebo matching BI 765845
Placebo matching BI 765845
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Infarct size measured as the percentage of left ventricular mass that is infarcted as detected using late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
At Day 5
Query!
Secondary outcome [1]
0
0
Infarct size measured as the percentage of left ventricular mass that is infarcted as detected using Late gadolinium enhancement (LGE) by cardiac magnetic resonance (CMR)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
At Day 90
Query!
Secondary outcome [2]
0
0
Difference in myocardial Infarct size (IS)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
At Day 5 and Day 90
Query!
Eligibility
Key inclusion criteria
1. Age =18 years (or legal age as per local regulations) at the time of signing informed consent
2. Signed and dated written informed consent in accordance with ICH Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
3. Male or female participants of non-childbearing potential. Male participants must be ready and able to use highly effective methods of birth control per ICH M3 (R2) for at least 5 days following investigational medicinl product (IMP) administration. Women who are not of childbearing potential are considered those that fulfil at least one or more of the following: aged 50 years or above and being naturally amenorrhoeic for at least 1 year (amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential) OR have premature ovarian failure confirmed by a gynaecologist OR have undergone bilateral salpingo-oophorectomy OR have undergone hysterectomy OR are affected by Turner syndrome OR have uterine agenesis
4. Onset of symptoms of myocardial ischaemia or myocardial infarct, according to patient report, within a duration of:
Part A: =1 hour (h) and =12 h prior to randomisation Part B: =1 h and =12 h prior to randomisation Further inclusion criteria apply.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Women of childbearing potential
2. Patients indicated for rescue PCI (i.e. after receiving fibrinolysis)
3. Patients presenting with cardiogenic shock defined as either systolic blood pressure (SBP) =90 mmHg persisting despite fluid challenge or inotropes/vasopressors use to maintain SBP >90 mmHg.
4. Known history of symptomatic heart failure (HF) with left ventricular systolic dysfunction (i.e. HFrEF) based on verbal medical history as reported by a trial participant or authorised representative
5. Known history of myocardial infarction (MI) with the exception of the index event (based on verbal medical history as reported by a trial participant or authorised representative)
6. Previous coronary artery bypass grafting (CABG) (based on verbal medical history as reported by a trial participant or authorised representative) Further exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/03/2027
Query!
Actual
Query!
Sample size
Target
350
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
South Western Sydney Local Health District - Liverpool
Query!
Recruitment hospital [2]
0
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [3]
0
0
The Northern Hospital - Epping
Query!
Recruitment hospital [4]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [3]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Alberta
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Manitoba
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Quebec
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Brno
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Prague 2
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Berlin
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Dortmund
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Dresden
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Frankfurt
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Freiburg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Hannover
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Heidelberg
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Langen
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Leipzig
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Ludwigshafen
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Mainz
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Trier
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Ulm
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Budapest
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Pecs
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Zalaegerszeg
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Bari
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Brescia
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Caserta
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Catania
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Cona (FE)
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Genova
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Massa
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Monza
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Palermo
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Rivoli (TO)
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Roma
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Torino
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Aichi, Kasugai
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Ibaraki, Higashiibaraki-gun
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kanagawa, Yokohama
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Miyagi, Sendai
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Okayama, Kurashiki
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Okayama, Okayama
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Osaka, Osakasayama
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Osaka, Osaka
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Tokyo, Shinjuku-ku
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Busan
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Gwangju
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Seoul
Query!
Country [59]
0
0
New Zealand
Query!
State/province [59]
0
0
Christchurch
Query!
Country [60]
0
0
New Zealand
Query!
State/province [60]
0
0
Grafton / Auckland
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Chrzanow
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Krakow
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Myszkow
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Opole
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Rzeszow
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Tychy
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Zabrze
Query!
Country [68]
0
0
Singapore
Query!
State/province [68]
0
0
Singapore
Query!
Country [69]
0
0
Slovakia
Query!
State/province [69]
0
0
Banska Bystrica
Query!
Country [70]
0
0
Slovakia
Query!
State/province [70]
0
0
Bratislava
Query!
Country [71]
0
0
Slovakia
Query!
State/province [71]
0
0
Nitra
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Barcelona
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
El Palmar
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Santiago de Compostela
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Sevilla
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Vigo
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Tainan
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Taipei
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Clydebank
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Leeds
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
London
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Manchester
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Newcastle upon Tyne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack. Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments look like BI 765845 treatments but do not contain any medicine. Participants are about 3 times as likely to receive BI 765845 than placebo. Participants are in the study for 3 months. During this time, they visit the study site 7 times and get 3 phone calls from the site staff. At the visits, the doctors use clinical tests to check the health of the heart. The results are compared between the BI 765845 and placebo groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06139328
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-800-243-0127
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06139328
Download to PDF